Bristol-Myers Squibb Company

NYSE:BMY

Drug Manufacturers - General

Healthcare
$59.56 -2.57%

-$1.42 today

Market cap
$121.75B
Beta
0.24
P/E (TTM)
15.1
EPS (TTM)
$3.56
Dividend yield
4.64%
52W Low $42.52High $62.89

Volume 9.54M

Average 11.50M

BMY EBITDA Margin

EBITDA as a percentage of revenue.

Bristol-Myers Squibb CompanyNYSE: BMY

EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026

EBITDA Margin widens to 39.2%

EBITDA Margin was 39.2% in Q2 FY2026, up 12.6 pp from a year earlier. On a trailing-twelve-month basis it was 34.2%, up 2.6 pp year over year. Over 3 fiscal years it narrowed by 10.0 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 19 analysts of 40.2% for the fiscal year ending Dec 2026, up from 31.6% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
39.2%+2.3 pp QoQ
Last fiscal yearDec 2025
31.6%+25.0 pp YoY
LTMJun 2026
34.2%+2.6 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+12.6 pp-9.8 pp-22.3 pp
1 year+25.0 pp+8.6 pp-16.4 pp
3 years-10.0 pp+9.7 pp+19.7 pp
5 years+9.2 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
31.6%
Year-over-year change
+25.0pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How BMY compares with its peers on the latest reported figures

  • BMY's LTM Jun 2026 EBITDA Margin of 34.2% is the 6th highest of the 11 companies compared; the peer median is 32.7%.
  • Its year-over-year change of +2.6 pp is the 4th highest of 11, against a peer median of -0.9 pp.
  • Over three fiscal years its change of -10.0 pp compares with a peer median of +7.9 pp.
BMY Competitors Peer median
EBITDA Margin for BMY and competitors
Company Period LTM level YoY 3-year change
LLYEli Lilly and CompanyLTM Jun 202654.4% +14.4 pp+18.3 pp
AMGNAmgen Inc.LTM Jun 202646.2% +0.7 pp-0.2 pp
NVSNovartis AGLTM Jun 202640.0% -1.1 pp+8.2 pp
ABBVAbbVie Inc.LTM Sep 202636.6% +15.1 pp-12.8 pp
AZNAstraZeneca PLCLTM Sep 202634.4% +3.4 pp+13.3 pp
BMYBristol-Myers Squibb CompanyLTM Jun 202634.2% +2.6 pp-10.0 pp
JNJJohnson & JohnsonLTM Sep 202631.0% -11.9 pp+10.3 pp
GSKGSK plcLTM Jun 202626.5% -0.7 pp+2.5 pp
PFEPfizer Inc.LTM Jun 202621.2% -10.4 pp-13.7 pp
MRKMerck & Co., Inc.LTM Jun 202621.0% -18.3 pp+7.6 pp
GILDGilead Sciences, Inc.LTM Jun 20264.4% -33.6 pp+13.7 pp
Peer median (excluding BMY) 32.7%-0.9 pp+7.9 pp

Competitors are the stored peer set for BMY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue46.39B46.16B45.01B48.3B48.2B
Cost of Revenue9.94B10.14B10.69B13.97B13.94B
Gross Profit36.45B36.02B34.31B34.33B34.26B
Gross Margin78.6%78.0%76.2%71.1%71.1%
Research & Development10.2B9.51B9.3B11.16B9.95B
Selling, General & Admin7.69B7.81B7.77B8.41B7.27B
Operating Expenses27.91B26.92B26.12B28.45B20.54B
Depreciation & Amortization10.69B10.28B9.76B9.6B4.01B
EBITDA20.12B19.22B19.37B3.17B15.23B
EBITDA Margin43.4%41.6%43.0%6.6%31.6%
Operating Income8.54B9.1B8.2B5.89B13.72B
Operating Margin18.4%19.7%18.2%12.2%28.5%
Interest Income00000
Interest Expense1.33B1.23B1.17B1.95B1.89B
Other Income / Expenses(439M)(1.39B)245M(14.27B)(4.4B)
Income Before Tax8.1B7.71B8.44B(8.38B)9.33B
Pre-Tax Margin17.5%16.7%18.8%-17.3%19.4%
Income Tax Expense1.08B1.37B400M554M2.27B
Net Income6.99B6.33B8.03B(8.95B)7.05B
Net Margin15.1%13.7%17.8%-18.5%14.6%
EPS (Basic)3.152.973.88(4.41)3.46
EPS (Diluted)3.122.953.86(4.41)3.45
Weighted Avg Shares2.22B2.13B2.07B2.03B2.04B
Weighted Avg Shares (Diluted)2.25B2.15B2.08B2.03B2.04B

Bristol-Myers Squibb Company

NYSE:BMY

Intrinsic Alpha fair value

Locked

Current Price

$59.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.